V
Vera Gorbounova
Researcher at Russian Academy
Publications - 20
Citations - 4037
Vera Gorbounova is an academic researcher from Russian Academy. The author has contributed to research in topics: Bevacizumab & Carboplatin. The author has an hindex of 12, co-authored 19 publications receiving 3793 citations. Previous affiliations of Vera Gorbounova include University of Texas MD Anderson Cancer Center & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Martin Reck,Joachim von Pawel,Petr Zatloukal,Rodryg Ramlau,Vera Gorbounova,Vera Hirsh,Natasha B. Leighl,J. Mezger,Venice Archer,Nicola Moore,Christian Manegold +10 more
TL;DR: Combining bevacizumab (7.5 or 15 mg/kg) with CG significantly improved PFS and objective response rate and offers clinical benefit for bevicizumAB-eligible patients with advanced NSCLC.
Journal ArticleDOI
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
Frank V. Fossella,José Rodrigues Pereira,Joachim von Pawel,Anna Pluzanska,Vera Gorbounova,E. Kaukel,K. Mattson,Rodryg Ramlau,Aleksandra Szczesna,Panagiotis Fidias,Michael Millward,Chandra P. Belani +11 more
TL;DR: DC resulted in a more favorable overall response and survival rate than VC, demonstrating that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
Journal ArticleDOI
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
Martin Reck,J. von Pawel,Petr Zatloukal,Rodryg Ramlau,Vera Gorbounova,Vera Hirsh,Natasha B. Leighl,J. Mezger,V. Archer,Nicola Moore,Christian Manegold +10 more
TL;DR: Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin–gemcitabine, and the PFS benefit did not translate into a significant OS benefit, possibly due to high use of efficacious second-line therapies.
Journal ArticleDOI
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk,Thomas J. Herzog,Stanley B. Kaye,Carolyn N. Krasner,Jan B. Vermorken,Franco M. Muggia,Eric Pujade-Lauraine,Alla Lisyanskaya,A. Makhson,Janusz Rolski,Vera Gorbounova,Prafull Ghatage,Mariusz Bidziński,Keng Shen,Hextan Y.S. Ngan,Ignace Vergote,Joo-Hyun Nam,Youn C. Park,Claudia Lebedinsky,Andres Poveda +19 more
TL;DR: When combined with PLD, trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer.
Journal ArticleDOI
Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704
Christian Manegold,J. von Pawel,Petr Zatloukal,Rodryg Ramlau,Vera Gorbounova,V. Hirsch,Natasha B. Leighl,J. Mezger,V. Archer,Martin Reck +9 more
TL;DR: This randomised, placebo-controlled phase III study compared two doses of B plus CG versus CG plus placebo to demonstrate the addition of bevacizumab to carboplatin/paclitaxel improved overall and progression-free survival in patients with advanced NSCLC.